# A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

> **NCT03633396** · PHASE2 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- Palmoplantar Pustulosis

## Interventions

- **BIOLOGICAL:** Imsidolimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03633396
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-20
- **Primary completion:** 2021-04-23
- **Final completion:** 2021-04-23
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03633396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03633396, "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03633396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*